Avalon Enters into Collaborative R&D Deal Worth a Potential US$200 M

doi:10.3833/pdr.v2007i82.358

Pharma Deals Review, Vol 2007, No 82 (2007)

Avalon Enters into Collaborative R&D Deal Worth a Potential US$200 M

Business Review Editor

Abstract

Avalon Pharmaceuticals entered into a R&D deal with Merck & Co. to identify and develop inhibitors for an undisclosed target that is involved in the development of cancer. The deal is worth up to US$200 M.

Full Text: pdf

Add comment

This work is licensed under a Creative Commons Attribution 3.0 License.